-DOCSTART- -X- O
Emerging -X- _ O
respiratory -X- _ O
coronaviruses -X- _ O
such -X- _ O
as -X- _ O
the -X- _ O
Severe -X- _ B-Patient
Acute -X- _ I-Patient
Respiratory -X- _ I-Patient
Syndrome -X- _ I-Patient
coronavirus -X- _ I-Patient
( -X- _ I-Patient
SARS-CoV -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
Middle -X- _ I-Patient
East -X- _ I-Patient
Respiratory -X- _ I-Patient
Syndrome -X- _ I-Patient
coronavirus -X- _ I-Patient
( -X- _ I-Patient
MERS-CoV -X- _ I-Patient
) -X- _ I-Patient
pose -X- _ O
potential -X- _ O
biological -X- _ O
threats -X- _ O
to -X- _ O
humans. -X- _ O
SARS -X- _ O
and -X- _ O
MERS -X- _ O
are -X- _ O
manifested -X- _ O
as -X- _ O
severe -X- _ O
atypical -X- _ O
pneumonia -X- _ O
associated -X- _ O
with -X- _ O
high -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
in -X- _ O
humans. -X- _ O
The -X- _ O
majority -X- _ O
of -X- _ O
studies -X- _ O
carried -X- _ O
out -X- _ O
in -X- _ O
SARS-CoV-infected -X- _ B-Patient
humans -X- _ I-Patient
and -X- _ I-Patient
animals -X- _ I-Patient
attribute -X- _ O
a -X- _ O
dysregulated -X- _ O
/ -X- _ O
exuberant -X- _ O
innate -X- _ O
response -X- _ O
as -X- _ O
a -X- _ O
leading -X- _ O
contributor -X- _ O
to -X- _ O
SARS-CoV-mediated -X- _ O
pathology. -X- _ O
A -X- _ O
decade -X- _ O
after -X- _ O
the -X- _ O
2002â€“2003 -X- _ O
SARS -X- _ O
epidemic -X- _ O
, -X- _ O
we -X- _ O
do -X- _ O
not -X- _ O
have -X- _ O
any -X- _ O
approved -X- _ O
preventive -X- _ O
or -X- _ O
therapeutic -X- _ O
agents -X- _ O
available -X- _ O
in -X- _ O
case -X- _ O
of -X- _ O
re- -X- _ O
emergence -X- _ O
of -X- _ O
SARS-CoV -X- _ O
or -X- _ O
other -X- _ O
related -X- _ O
viruses. -X- _ O
A -X- _ B-Outcome
strong -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
generated -X- _ I-Outcome
against -X- _ I-Outcome
the -X- _ I-Outcome
spike -X- _ I-Outcome
( -X- _ I-Outcome
S -X- _ I-Outcome
) -X- _ I-Outcome
glycoprotein -X- _ I-Outcome
of -X- _ I-Outcome
SARS-CoV -X- _ I-Outcome
is -X- _ I-Outcome
completely -X- _ I-Outcome
protective -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
susceptible -X- _ I-Outcome
host. -X- _ I-Outcome
However -X- _ I-Outcome
, -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
titers -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
memory -X- _ I-Outcome
B -X- _ I-Outcome
cell -X- _ I-Outcome
response -X- _ I-Outcome
are -X- _ I-Outcome
short- -X- _ I-Outcome
lived -X- _ I-Outcome
in -X- _ I-Outcome
SARS-recovered -X- _ I-Outcome
patients -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
antibody -X- _ I-Outcome
will -X- _ I-Outcome
target -X- _ I-Outcome
primary -X- _ I-Outcome
homologous -X- _ I-Outcome
strain. -X- _ I-Outcome
Interestingly -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
acute -X- _ I-Outcome
phase -X- _ I-Outcome
of -X- _ I-Outcome
SARS -X- _ I-Outcome
in -X- _ I-Outcome
humans -X- _ I-Outcome
is -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
severe -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
blood. -X- _ I-Outcome
Surprisingly -X- _ O
, -X- _ O
only -X- _ O
a -X- _ O
limited -X- _ O
number -X- _ O
of -X- _ O
studies -X- _ O
have -X- _ O
explored -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
the -X- _ O
T -X- _ O
cell-mediated -X- _ O
adaptive -X- _ O
immune -X- _ O
response -X- _ O
in -X- _ O
respiratory -X- _ O
coronavirus -X- _ O
pathogenesis. -X- _ O
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
discuss -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
anti-virus -X- _ O
CD4 -X- _ O
and -X- _ O
CD8 -X- _ O
T -X- _ O
cells -X- _ O
during -X- _ O
respiratory -X- _ O
coronavirus -X- _ O
infections -X- _ O
with -X- _ O
a -X- _ O
special -X- _ O
emphasis -X- _ O
on -X- _ O
emerging -X- _ O
coronaviruses -X- _ O
. -X- _ O

